HORIZON | IMMUTOL 1st Progress Meeting

Advanced Antigen-Specific Dendritic Cells Based Therapy to Re-establish Tolerance in Immune-Mediated Diseases.

Advanced Antigen-Specific Dendritic Cells Based Therapy to Re-establish Tolerance in Immune-Mediated Diseases.
June 14, 2024

Last week, IMMUTOL partners gathered in Barcelona for the 1st Annual Meeting of the IMMUTOL project (6-7 June) to celebrate the progress of this European Union funded project. Asphalion, in charge of the regulatory activities, presented a summary of the regulatory road map (deliverable 6.1) within WP6. Preliminary results from partners were presented, and a roundtable on the hot topic of target patient selection guided the project’s progression through the 2nd year.

IMMUTOL’s objective is to pave the way for new tolerogenic cell-based therapies to cure/reverse several autoimmune conditions, developing a more potent and durable treatment for autoimmune diseases with an unmet medical need, particularly Multiple Sclerosis.

Multiple Sclerosis is a chronic inflammatory demyelinating disease of the central nervous system. In Europe alone, there are around 500,000 people suffering from this disease, which is often diagnosed in individuals (mostly women) aged 20 to 40. With increasing disability, this incurable disease greatly reduces the quality of life for patients and imposes a high burden on society in terms of the cost of therapy and chronic need for care.

The IMMUTOL consortium gathers experts and institutions from different sectors, including research institutions, academia, patients’ associations, hospitals, and corporate SMEs.

Check out the IMMUTOL website for more information on the project. For further information or regulatory support for your HORIZON project, contact us at [email protected].

Search News & Events

  • Filter by category

Share

Related news and events

HORIZON EUROPE | NABIHEAL progress meeting

Two years into the NABIHEAL project, Asphalion experts Marta Rayo Lunar and Sergio Veiga attended the consortium meeting in Zagreb, hosted by IMI, to review

HORIZON EUROPE PROJECT | KeratOPrinter Kick-Off Meeting

Corneal blindness affects over 11.7 million people worldwide, yet only 1 in 70 patients receive a corneal transplant due to a severe donor shortage. The KeratOPrinter project aims to address this gap by developing a groundbreaking 4D bioprinting suite capable of producing fully functional, biocompatible human corneas. Combining expertise from world-class partners, the project focuses on scalable cell sources, advanced bioinks, high-precision bioprinting, clinical handling solutions, regulatory compliance, and a strong collaborative network. By 2035, KeratOPrinter seeks to revolutionize corneal transplantation and restore vision for millions.

ARDAT PROJECT

A new year, new classes, and a deep dive into advanced therapies, including discussions on the ARDAT project, as part of the University of Sheffield’s

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting